Golexanolone affords sustained microglia and astrocytes activation improvement in a rat model of Parkinson’s disease
Sustained improvement of glial activation in SN and striatum would be a key mechanism in the improvement of PD symptoms by golexanolone.
Authors
- Magnus Doverskog (ORCID: https://orcid.org/0000-0001-8589-0724)
- Gergana Mincheva (ORCID: https://orcid.org/0000-0002-2981-7060)
- María A. Pedrosa (ORCID: https://orcid.org/0000-0001-9553-8513)
- Maribel Vázquez (ORCID: https://orcid.org/0000-0002-6184-3103)
- Marta Llansola (ORCID: https://orcid.org/0000-0002-5565-5907)
- Vicente Felipo (ORCID: https://orcid.org/0000-0003-3145-9538)
- Thomas P. Blackburn (ORCID: https://orcid.org/0000-0001-9317-7507)
- Lola Vázquez
Institutions
- Asarina Pharma (Sweden) (SE)
- Centro de Investigacion Principe Felipe (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.3389/fimmu.2025.1654664
- Citations
- 1
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.84